Recent findings from a comprehensive study presented at the ECTRIMS annual meeting highlight a troubling trend in the treatment of relapsing multiple sclerosis (MS). An analysis of French registry data indicates that women are significantly less likely than men to receive essential disease-modifying treatments (DMTs) for their condition. This disparity raises critical questions about factors influencing treatment decisions and the long-term consequences for women’s health in the context of MS.
The study, led by Dr. Antoine Gavoille from Hospices Civils de Lyon, incorporated data from 22,657 patients diagnosed with relapsing MS, predominantly female (74.2%). The average age at diagnosis was around 30 years old, a pivotal period for both treatment and personal life choices such as family planning. Over an extensive follow-up period averaging 11.6 years, the data revealed that women experienced a significantly lower likelihood of being prescribed any DMT (OR 0.92) and high-efficacy DMTs (OR 0.80). These findings starkly illustrate a pattern of “therapeutic inertia,” predominantly disadvantaging women in a disease landscape where timely and effective treatment is crucial for managing disease activity.
The term “therapeutic inertia” implies a reluctance among healthcare providers to initiate or escalate treatment despite clinical indications warranting such actions. Co-author Dr. Sandra Vukusic emphasized that this inertia can have severe repercussions for women, potentially resulting in the progression of lesions and an amplified risk of long-term disability. In an era where effective DMTs can dramatically alter the disease trajectory, ignoring the particular needs of women with MS represents a critical failure in care and intervention.
A notable factor influencing treatment decisions for women in their childbearing years is the fear and anticipation of pregnancy. The study draws attention to how preemptive concerns about potential pregnancy impacts treatment choices, often leading to under-treatment of women. Neurologists may hesitate to prescribe DMTs due to uncertainties about managing pregnancy-related complications, which could further dissuade women from pursuing necessary treatments. This hesitancy is not merely a reflection of clinician bias but also embodies the complex interplay of medical judgment and patient anxiety about the risks associated with DMTs during pregnancy.
Women are understandably cautious about the implications of treatment on fetal health, including fears of congenital malformations or other adverse outcomes. Such apprehensions can lead to a considerable gap in treatment between genders, where women might avoid or delay necessary interventions. Moreover, if a physician exhibits uncertainty, it increases the discomfort for women, further complicating the decision-making process.
Detailed investigations into the treatment patterns over time revealed significant variability in the usage of specific DMTs among genders. While initially, certain therapies like Interferon beta and natalizumab were less frequently prescribed to women, the patterns shifted over time, with some treatments ultimately reaching parity. Notably, medicaments like teriflunomide and S1PR-modulators were consistently underprescribed to women, indicating a systemic bias in treatment allocation.
What’s alarming is that these treatment disparities became pronounced approximately five years into the disease progression and three years for high-efficacy DMTs, underscoring a critical window where intervention could yield substantial benefits. Furthermore, a sub-analysis revealed that women were particularly under-treated around nine months prior to conception, implying that decision-making around pregnancy profoundly impacts treatment approaches.
The findings from this extensive study call for a reevaluation of treatment protocols for younger women diagnosed with MS. Dr. Vukusic expressed a salient point indicating that many women may not receive the most effective therapies at the most beneficial time due to unfounded concerns about pregnancy risks that may never materialize. Given the evolving landscape of DMTs and their effectiveness, it is vital to address these biases and perceptions.
Healthcare providers must recognize the dual narrative of MS management—mitigating disease progression while addressing the unique needs of female patients, particularly in reproductive-age groups. To improve treatment outcomes, it’s imperative to ensure informed, evidence-based discussions between patients and providers that alleviates concerns about pregnancy and emphasizes timely interventions.
Gender disparities in MS treatment highlight an urgent need for adjustments within clinical practices and societal perceptions surrounding women’s health in the realm of chronic diseases. By dismantling barriers to care and addressing therapeutic inertia, we can empower women to access the full spectrum of treatments available, all while honoring their reproductive choices. Ultimately, the fight against MS requires a unified approach to ensure that no gender is at a disadvantage in receiving the care they need and deserve.